Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Study Details
Study Description
Brief Summary
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen.
Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Eighteen participants will be enrolled, ideally within one year. Participants will be enrolled regardless of OI type since Bronchial Wall Thickening, a finding we are attempting to validate, was observed in all types of OI. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI. Smokers will not be excluded.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Adults with OI 18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI. This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded. |
Outcome Measures
Primary Outcome Measures
- proportion of restrictive lung physiology [12 months]
FEV1/FVC greater than or equal to 80%, which is obtained from PFT
Secondary Outcome Measures
- Presence and severity of Bronchial Wall Thickening [12 months]
measurement of percent of bronchial diameter subsumed by wall thickness
- Vital lung capacity [12 months]
Vital capacity/total lung capacity/chest volume prediction based on 1) readings by trained chest CT readers and 2) 3-D lung imaging calculation
- Presences of pulmonary fibrosis [12 months]
Presence of pulmonary fibrosis based on readings by trained chest CT readers
- Change in lung tissue [12 months]
location of bronchiectasis, and presence of atelectasis based on readings by trained chest CT readers
Other Outcome Measures
- Scoliosis [12 months]
Measurement of spinal scoliosis, kyphosis, lordosis and vertebral fractures including curve measurement based on standing plane films of thorax/abdomen exposed for bone imaging
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf
-
Individuals ages 18 and older of all races and sexes
-
Individuals who have been diagnosed with OI clinically and/or genetically
Exclusion Criteria:
-
Individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness.
-
Individuals with other skeletal dysplasia or genetic diagnosis
-
Individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California Los Angeles | Los Angeles | California | United States | 90095 |
| 2 | Kennedy Krieger Institute / Hugo W. Moser Research Institute | Baltimore | Maryland | United States | 21205 |
| 3 | Hospital for Special Surgery | New York | New York | United States | 10021 |
Sponsors and Collaborators
- Baylor College of Medicine
Investigators
- Principal Investigator: Vernon Sutton, MD, Baylor College of Medicine
- Study Chair: Kathleen Raggio, Hospital for Special Surgery, New York
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H49848